CONMED
CNMD
275 hedge funds and large institutions have $3.59B invested in CONMED in 2023 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 97 increasing their positions, 90 reducing their positions, and 41 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 41
5% more funds holding
Funds holding: 263 → 275 (+12)
8% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 90
0.12% more ownership
Funds ownership: 115.54% → 115.67% (+0.12%)
25% less capital invested
Capital invested by funds: $4.8B → $3.59B (-$1.21B)
27% less call options, than puts
Call options by funds: $21.9M | Put options by funds: $29.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$26.2M |
| 2 |
Two Sigma Investments
New York
|
+$23.8M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.3M |
| 4 |
Two Sigma Advisers
New York
|
+$13.1M |
| 5 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$53.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$47.2M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$27.9M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$20.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20M |
CNMD Hedge Fund Activity: Q3 2023 in Review
275 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q3 2023, worth a combined $3.59B — down 25% from $4.8B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new CNMD positions and 41 closed out — a net gain of 13 holders — while 97 added to existing stakes and 90 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $26.2M. The largest seller was JP Morgan Chase, cutting an estimated $53.8M.
- 275 institutional investors held CONMED (CNMD) as of Q3 2023, up from 263 in Q2 2023.
- Funds reported $3.59B of CONMED stock for Q3 2023, down 25% quarter-over-quarter.
- 54 funds opened new CONMED positions in Q3 2023 and 41 closed out, a net change of +13 holders.
- The largest CONMED buyer in Q3 2023 was Morgan Stanley, an estimated $26.2M added.
- The largest CONMED seller in Q3 2023 was JP Morgan Chase, an estimated $53.8M sold.
Based on aggregated 13F filings for Q3 2023.